MedPath

Effect of preoperative concurrent chemoradiotherapy in patients with adenocarcinoma of esophagus

Not Applicable
Conditions
Health Condition 1: null- patients with ECOG (0,1,2) - Good performance status
Registration Number
CTRI/2013/09/003981
Lead Sponsor
not applicable
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
160
Inclusion Criteria

1.Age < 70 years

2.Adenocarcinoma

3.Good performance status (Eastern Cooperative Oncology Group [ECOG] grades 0, 1 and 2) i.e the patient should not be spending more than 50% of his time in Bed.

4.Swallowing capacity at preop or preop neoadjuvant is a minimum of oral intake (liquid or semisolid)

5.Contrast enhanced computerized tomographic (CECT) scan suggesting a potentially resectable lesion. The features of resectability assessed on CECT scan will include - no evidence of infiltration of mediastinal structures such as the aorta (angle of contact <900), no obliteration of the triangular fat space between the esophagus, aorta, and spine, and pericardium, and no evidence of tracheobronchial fistula or tumor extension into the airway lumen.

6.No evidence of distant metastasis on CECT of neck , thorax and abdomen.

Exclusion Criteria

1.Patient refuses consent for the study

2.Co-morbid conditions which would preclude oesophagectomy

a.Poor performance status (ECOG > 2)

b.American Society of Anesthesiologists class IV

3.Metastatic disease detected on evaluation

4.Involvement of mediastinal structures as described in the inclusion criteria

5.Carcinoma involving upper third of the esophagus.

6.Previous radiotherapy or chemotherapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
resectability rate, postoperative morbidity and operative mortalityTimepoint: resectability rate, postoperative morbidity and operative mortality
Secondary Outcome Measures
NameTimeMethod
treatment compliance , early disease control (at 1 year) and assess the treatment toxicity of preoperative chemoradiation.Timepoint: till 2 years
© Copyright 2025. All Rights Reserved by MedPath